tambiciclib (SLS009) / GenFleet Therap, SELLAS Life Sciences - LARVOL DELTA

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer (The Manila Times) - "SLS009 demonstrated substantially greater single-agent activity than daraxonrasib in the daraxonrasib-resistant model, inducing 17.9% apoptosis versus 2.8% with daraxonrasib and 14.5% necrosis versus 2.7%; The combination of SLS009 and daraxonrasib further increased cancer cell death, inducing 36.5% apoptosis and 30.6% necrosis, compared with 17.9% and 14.5%, respectively, with SLS009 alone and 2.8% and 2.7%, respectively, with daraxonrasib monotherapy; SLS009 combined with ZEN3694 demonstrated synergistic activity, producing greater apoptosis and necrosis than either agent alone; The SLS009/ZEN3694 combination produced sustained suppression of MYC RNA and reduced expression of MYC and MCL-1 proteins, consistent with disruption of transcriptional pathways supporting tumor cell survival."

Preclinical • Pancreatic Ductal Adenocarcinoma

Phase 2a Study of SLS009, a Highly Selective CDK9 Inhibitor, in Combination with Azacitidine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia after Prior Venetoclax Treatment (ASH 2024) - "Clinical activity was seen particularly in pts with ASXL1 mutation which may be a subpopulation of patients with preferential sensitivity to SLS009 + AZA/VEN. Further development will be focused on AML-MR patients with and without ASXL1 mutations."

Combination therapy • P2a data • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Myelodysplastic Syndrome • Nephrology • Neutropenia • Oncology • Renal Disease • ASXL1 • FLT3 • IDH1 • IDH2 • MCL1 • RUNX1 • SRSF2 • TET2 • TP53

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer (GlobeNewswire) - "Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer...'The presentations will explore the potential for SLS009 to create synthetic lethal interactions through rational combinations with BET- and KRAS-directed approaches, as well as its potential to exploit MYC-associated vulnerabilities. We look forward to sharing this work with the scientific community later this month'."

Preclinical • Pancreatic Ductal Adenocarcinoma

Potential expansion of SLS009 into solid cancers (GlobeNewswire) - "SLS009 has demonstrated the ability to act as a single agent in PDAC cells largely resistant to leading RAS inhibitors and synergize with the RAS inhibition mechanism of action. The data from these preclinical experiments are expected to be presented at an upcoming medical conference."

Preclinical • Pancreatic Ductal Adenocarcinoma

Ongoing dosing of SLS009 in earlier-line AML (GlobeNewswire) - "28 patients have been enrolled, and enrollment and dosing continue in the ongoing 80-patient Phase 2 trial in newly diagnosed AML patients, including those who become refractory early to AZA/VEN treatment identified through extensive transcriptomics, genomics, and proteomics models. Topline data expected in Q4 2026."

P2 data • Trial status • Acute Myelogenous Leukemia

IRST204.09: A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone (clinicaltrialsregister.eu) - P1/2 | N=40 | Not yet recruiting | Sponsor: Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., IIS La Fe

New P1/2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Ongoing dosing of SLS009 in earlier-line AML (SELLAS Life Sciences Press Release) - "SELLAS has initiated an 80-patient Phase 2 trial in newly diagnosed AML patients, including those who become refractory early to AZA/VEN treatment identified through extensive transcriptomics, genomics, and proteomics models. The topline data are expected in Q4 2026."

P2 data • Trial status • Acute Myelogenous Leukemia

Tambiciclib (SLS009), a CDK9 inhibitor, promotes apoptosis and suppresses MCL-1 levels in AML cell lines (AACR 2026) - P1/2 | "These results suggest that AML cell lines undergo cell death and apoptosis at low nanomolar concentrations of tambiciclib. Preliminary analysis of apoptotic molecules and pathways suggests a mechanism involving MCL-1 and survivin. With ongoing investigations into the dose and schedule of tambiciclib, our future directions include optimizing the use of tambiciclib in combination therapy to leverage the mechanistic effects of CDK9 inhibition and provide a novel therapeutic approach to treating patients with high-risk AML."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Mantle Cell Lymphoma • Oncology • ANXA5 • ASXL1 • BIRC5 • CASP3 • FLT3 • GLI2 • MCL1 • NRAS • TP53

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference (GlobeNewswire) - "Changes in caspase-3 and MCL-1 were observed as early as 6 hours after completion of treatment and became more pronounced at 24 hours. Lower levels of MCL-1 and survivin were strongly correlated with increased apoptosis....Notably, SLS009 demonstrated activity even in AML models harboring ASXL1 and TP53 mutations, which are typically associated with high resistance and poor clinical outcomes."

Preclinical • Acute Myelogenous Leukemia

GFH009X2101: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML (clinicaltrials.gov) - P1/2 | N=160 | Recruiting | Sponsor: Sellas Life Sciences Group | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Myelodysplastic Syndrome • Oncology • Primary Central Nervous System Lymphoma • ASXL1 • BCOR • DDX41 • FLT3 • IDH1 • IDH2 • KRAS • NPM1 • PD-L1 • SF3B1 • SRSF2 • STAG2 • U2AF1 • ZRSR2

SELLAS Life Sciences…announced the first patient has been enrolled in its randomized Phase 2 trial evaluating SLS009 (tambiciclib), a highly selective CDK9 inhibitor in newly diagnosed, first-line acute myeloid leukemia (AML) patients (GlobeNewswire) - "The newly initiated NCT04588922 is designed to enroll approximately 80 patients and includes two AML cohorts with high unmet need and greatest potential benefit...SELLAS’ predictive biomarker and AI assisted precision medicine models to be utilized. Topline data expected in Q4 2026."

P2 data • Trial status • Acute Myelogenous Leukemia

SELLAS Life Sciences Group, Inc…announced that it has entered into an agreement with IMPACT-AML, a European collaborative initiative dedicated to advancing innovative treatments for patients with acute myeloid leukemia (AML) (GlobeNewswire) - "Under the agreement, the IMPACT-AML network will conduct a clinical study evaluating SLS009, a highly selective CDK9 inhibitor, enabling access to multiple European clinical sites and patients....Enrollment in the first part of the trial for newly diagnosed patients is expected to begin at U.S. sites in Q1 2026, followed by initiation at European sites in Q2 2026, subject to regulatory and site readiness."

Commercial • Acute Myelogenous Leukemia

Tambiciclib (SLS009), a novel, potent CDK9 inhibitor is effective in killing ASXL1 mutated and TP53 knockout Acute Myeloid Leukemia cell lines (ASH 2025) - "Tambiciclib has steadily advanced in early-phase clinical trials and has already shown promising clinical benefits when combined with azacitidine, a hypomethylating agent, and venetoclax, a BCL-2 inhibitor; however, there is still a need for optimization of the treatment window for maximal benefit. Inhibition of CDK9 with tambiciclib is a promising and effective approach for inducing cell death in AML. Our preliminary data warrants further investigation to optimize the therapeutic window for tambiciclib treatment in repeated doses and combination therapies."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • ASXL1 • GLI2 • MCL1 • MEIS1 • MYC • TP53

Phase 2 study of SLS009 in combination with azacitidine and venetoclax for relapsed/refractory AML with MDS-related changes (AML-MR) after prior venetoclax treatment (ASH 2025) - "Addition of SLS009 30 mg IV BIW to AZA/VEN was found to be safe and feasible without DLTs. Clinicalefficacy was seen in pts with AML-MR, with a signal of activity in pts with ASXL1 mutated AML. Pts withonly 1 line of ven-based prior therapy experienced the greatest benefit in terms of response and longterm survival, implying a role in patients progressing after HMA + ven."

Combination therapy • P2 data • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Myelodysplastic Syndrome • Neutropenia • Thrombocytopenia • ASXL1 • CDK9 • MCL1 • MECOM • RUNX1 • SRSF2 • TP53

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 (GlobeNewswire) - "SLS009 in combination with AZA/VEN demonstrated clinically meaningful activity in patients with R/R AML-MR, and among the 35 evaluable patients, the overall response rate (CR+CRi+MLFS) was 46%, including 29% achieving CR/CRi. Patients harboring ASXL1 or TP53 mutations achieved response rates of 48% (19% CR/CRi) and 57% (29% CR/CRi), respectively. The median overall survival (mOS) was exceedingly higher than the expected 2.6 months in this R/R AML patient population, and in the least pretreated cohort, mOS reached 8.9 months....Study expansion to evaluate SLS009 plus AZA/VEN in newly diagnosed AML with high-risk features is planned for Q1 2026."

P2 data • Trial status • Acute Myelogenous Leukemia

SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) - "In addition, an abstract highlighting the proposed mechanism of action of SLS009 has been published on the ASH Annual Meeting website and will also be available in Blood. The published preclinical abstract describes studies demonstrating the cytotoxic effects of SLS009 in AML cell lines with leukemia-driving mutations."

P2 data • Preclinical • Acute Myelogenous Leukemia

CDK9 inhibition enhances venetoclax activity and prolongs survival in a T-PLL patient-derived xenograft model (ESMO 2025) - "The model was expanded and used in a pre-clinical trial to evaluate a novel therapeutic combination using SLS009 (GFH009), a specific CDK9 inhibitor and Venetoclax, a BCL2 inhibitor. Our T-PLL PDX model can be used to evaluate the effect of new drugs for T-PLL in a preclinical setting. Legal entity responsible for the study The authors."

Preclinical • Hematological Malignancies • Leukemia • Oncology • Prolymphocytic Leukemia • IL2RG • PRKDC • PTPRC

SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire) - "The results highlight an in vivo patient-derived xenograft (PDX) model of relapsed/refractory T-PLL that reproduced key human clinicopathological features of the disease....Both SLS009 monotherapy and the combination prolonged overall survival (7.4 weeks and 7.9 weeks, respectively) compared to venetoclax alone (4.4 weeks)..."

Preclinical • T-Cell Prolymphocytic Leukemia

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update (GlobeNewswire) - "SELLAS will also present an update of SLS009....plans for a newly diagnosed and frontline AML study anticipated to begin in the first quarter of 2026."

New trial • Trial status • Acute Myelogenous Leukemia

Preclinical Efficacy of SLS009 in T-Cell Prolymphocytic Leukemia (T-PLL) to be Showcased at ESMO 2025 (GlobeNewswire) - "The poster, entitled, CDK9 Inhibition Enhances Venetoclax Activity and Prolongs Survival in a T-PLL Patient-Derived Xenograft Model, will be presented during the ESMO congress to be held in Berlin, 17-21 October 2025."

Preclinical • T-Cell Prolymphocytic Leukemia

GFH009X2101: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies (clinicaltrials.gov) - P1/2 | N=160 | Recruiting | Sponsor: Sellas Life Sciences Group | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial primary completion date • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology

Front Line Trial Planning Underway Following FDA Guidance (SELLAS Life Sciences Press Release) - "Following a productive end of Phase 2 meeting, the FDA recommended that SELLAS proceeds into a trial to include newly diagnosed, first-line AML patients eligible for venetoclax/azacitidine (aza/ven) therapy, where the agency believes clinical benefit might be greatest; The randomized 80-patient trial is currently in preparation and is expected to begin enrollment by Q1 2026. The trial will include two groups: Predictive biomarker cohort: Newly diagnosed patients unlikely to benefit from standard aza/ven therapy based on molecular profiling; Early resistance cohort: Patients who initiate treatment with aza/ven but demonstrate confirmed lack of any response after two treatment cycles; This precision approach allows SELLAS to target subpopulations with high unmet need and greatest potential for benefit."

FDA event • New trial • Acute Myelogenous Leukemia

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML... (SELLAS Life Sciences Press Release) - P1/2a | N=160 | NCT04588922 | Sponsor: Sellas Life Sciences Group | "The results exceeded the pre-specified ORR threshold of 20%, demonstrating robust clinical activity and supporting advancement into late-stage development; The ORR in all evaluable patients was 33% across all cohorts and dose levels and 40% for the 30mg BIW dose level; At the 30 mg BIW dose, among AML MR patients, the ORR was 44%; The highest efficacy was observed among patients with ASXL1 mutations, with an ORR of 50% (9/18) at 30 mg BIW dose levels and M4/M5 patients with 50% (6/12) ORR; The mOS surpassed the historical benchmark of best available therapy of 2.4 months1 for patients who received one prior line of therapy and 1.8 months for those who received more than one prior line of therapy....The addition of SLS009 to the venetoclax/azacitidine regimen was well tolerated and did not result in increased toxicities compared to ven/aza alone. No dose-limiting toxicities were observed across all dose levels."

P2 data • Acute Myelogenous Leukemia

In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines. (ASCO 2025) - "Results indicate that ASXL1 mutations may be oncogenic drivers in some solid tumors, like CRC MSI-H, similar to those in AML and that efficacy of CDK9 inhibition with SLS009 may be similar in some solid tumors to the efficacy observed in AML."

Preclinical • Acute Myelogenous Leukemia • Colorectal Cancer • Hematological Malignancies • Leukemia • Microsatellite Instability • Oncology • Solid Tumor • ASXL1 • MSI • TP53

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting (GlobeNewswire) - "In a panel of cell lines, SLS009 demonstrated potent anti-proliferative activity: In 50% (4/8) of ASXL1 mutant cell lines showed an IC50<100 nM, compared to 0% (0/4) of ASXL1 wild-type lines; Among cell lines harboring ASXL1 frameshift mutations (FSMs), 75% (3/4) responded with IC50 <100 nM versus only 12.5% (1/8) in cell lines without FSMs; All cell lines (3/3) with ASXL1 FSMs in the 637-638 protein region responded to treatment with SLS009; In cell lines with IC50 <100 nM, 75% (3/4) also demonstrated IC99 values below 100 nM, indicating steep dose response curve."

Preclinical • Colorectal Cancer